Cheryl Swanson
Contributor since: 2013
Latest Articles
Jazz Pharma: No Longer Singing The Blues With Multiple 2016 Catalysts
Illumina's $20-$200 Billion Quest - Don't Miss The Opportunity
Alexion: 2 Global Drug Rollouts, But Upside Already Priced In
Regeneron's Mega-Blockbuster Potential With Praluent: CVS Health Sees It, So Why Don't More Analysts?
Regeneron Jumps Ahead In $10 Billion Race For Next Generation Cardio Drugs
Will Medivation Kick J&J To The Curb For This $9 Billion Market?
Seattle Genetics And Agios Pharmaceuticals: Opportunity Or Danger?
DaVita's Outlook For 2015: Don't Overstay The Festivities
Why Apple's Product Launch Rocked
Amazon Plus Twitch Equals A Whole New Game
Why Tim Cook Wants Mom And Pop To Buy Apple
Qualcomm: A Huge New Frontier Makes It A Shrewd Buy
Intuitive Surgical: Game Over Or Game Just Begun?
Wearable Tech: Forget Google And Apple, Think Different (Part II)
Wearable Tech: Forget Google And Apple, Think Different (Part I)
Intel: Don't Be Left Holding The Bag
Are Generic Drug Stocks The Cure For A Hung-Over Health Care Market?
Is Berkshire Pick DaVita HealthCare The Perfect Wave?
Could The Grinch Steal Apple's Christmas?
As Obamacare Rolls Out, UnitedHealth Rolls Over The Competition
Don't Be Scared Off By Risks In The Cancer Biotech Space
Sink Your Teeth Into This: Pet Stocks Are On The Rise